GlassScriptPhysician profile
Jae Wook Nam
NPI 1477581999
$7,895.18
in general payments reported to CMS, 2019-2025
40 companies · $1,136 in 2025
The $1,136 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,021 · 2020: $765 · 2021: $1,173 · 2022: $1,421 · 2023: $1,240 · 2024: $1,138 · 2025: $1,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,514.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,876.95 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $860.38 | 2019-2023 | Trulance, Xifaxan, Plenvu |
| Gilead Sciences, INC. | $700.94 | 2019-2025 | |
| Janssen Biotech, INC. | $462.13 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $456.99 | 2019-2025 | |
| Genzyme Corporation | $431.70 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $355.45 | 2019-2025 | Entyvio, Gattex |
| Intercept Pharmaceuticals, INC. | $292.28 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $280.73 | 2022-2025 | Dupixent |
| Celgene Corporation | $276.89 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $247.09 | 2019-2024 | Linzess |
| Lilly USA, LLC | $134.30 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $131.15 | 2019-2024 | Suflave, Sutab |
| Ardelyx, INC. | $126.64 | 2022-2025 | Ibsrela |
| Daiichi Sankyo INC. | $118.76 | 2020-2024 | Injectafer |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $112.77 | 2019-2023 | Rebyota |
| Amgen INC. | $102.68 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $102.60 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $99.60 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $95.54 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $81.22 | 2019-2023 | Dificid |
| Organon LLC | $60.03 | 2023-2024 | Renflexis, Hadlima |
| Redhill Biopharma INC. | $51.96 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $40.37 | 2025 | Voquezna |
| Aimmune Therapeutics, INC. | $37.49 | 2024 | |
| Intra-Sana Laboratories | $37.43 | 2021-2022 | |
| Csl Behring | $36.76 | 2022-2023 | Haegarda |
| Fresenius Kabi USA, LLC | $34.99 | 2023-2024 | Idacio |
| Boston Scientific Corporation | $33.26 | 2021-2022 | |
| Ucb, INC. | $31.59 | 2019 | |
| Alnylam Pharmaceuticals INC. | $25.82 | 2022 | |
| Allergan, INC. | $24.75 | 2019 | |
| Qol Medical, LLC | $21.10 | 2021 | |
| Olympus America INC. | $19.48 | 2019 | |
| Biocon Biologics INC | $19.03 | 2025 | Yesintek |
| Celltrion USA INC. | $17.96 | 2025 | Vegzelma |
| Medtronic, INC. | $17.06 | 2025 | Pillcam |
| Shionogi INC | $15.98 | 2019 | |
| Alfasigma USA, INC. | $12.26 | 2020 | |
| Micro-Tech Endoscopy USA, INC. | $11.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jae Nam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.